Study guide
8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies
BCOP Board Certified Oncology Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & BCOP Exam Foundations
1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy
2 Chapter 2: Cancer Biology & Pathophysiology
2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion
3 Chapter 3: Genomic Biomarkers & Molecular Targets
3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6
4 Chapter 4: Diagnostics, Staging & Clinical Assessment
4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention
5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens
5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins
6 Chapter 6: Targeted Small-Molecule Therapies
6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways
7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy
7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics
8 Chapter 8: Breast & Gynecologic Malignancies
8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies
9 Chapter 9: Thoracic & Skin Malignancies
9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers
10 Chapter 10: Gastrointestinal & Genitourinary Malignancies
10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas
11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma
11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP
12 Chapter 12: Lymphomas & Stem Cell Transplantation
12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease
13 Chapter 13: Supportive Care & Toxicity Management
13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes
14 Chapter 14: Hazardous Drug Handling & Compounding Safety
14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response
15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification
15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination
16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation
16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal
17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education
17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology
8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies
Key Takeaways Explain This Topic AI
First-line maintenance therapy in advanced high-grade serous ovarian cancer is dictated by homologous recombination repair deficiency (HRD) and BRCA status: germline/somatic BRCA-mutated tumors derive profound, long-term overall survival benefit from olaparib maintenance for 2 years (SOLO-1), HRD-positive tumors benefit from olaparib + bevacizumab (PAOLA-1) or niraparib (PRIMA), whereas HRD-negative/proficient tumors derive minimal benefit from PARP monotherapy.
Mirvetuximab soravtansine (anti-FRalpha ADC with DM4 maytansinoid payload) is standard-of-care for FRalpha-positive (>=75% of cells with >=2+ intensity) platinum-resistant ovarian cancer (MIRASOL trial); pharmacists must enforce protocolized ophthalmic care (topical steroid drops, lubricating artificial tears) to prevent severe corneal keratopathy.
Endometrial cancer classification incorporates TCGA molecular stratification: POLE ultramutated (favorable prognosis), dMMR/MSI-High (highly checkpoint inhibitor-responsive), p53 abnormal (aggressive serous-like, poor prognosis), and NSMP; frontline therapy for advanced dMMR endometrial cancer integrates dostarlimab or pembrolizumab with carboplatin + paclitaxel (RUBY / NRG-GY018).
Second-line therapy for recurrent mismatch repair proficient (pMMR) endometrial cancer combines lenvatinib 20 mg PO daily with pembrolizumab 200 mg IV Q3W (KEYNOTE-775), requiring proactive management of severe VEGFR-mediated hypertension, proteinuria, and fistula risks.
Locally advanced cervical cancer is cured with definitive concurrent chemoradiation (CCRT: external beam radiation + brachytherapy + weekly radiosensitizing cisplatin 40 mg/m2), while persistent/metastatic cervical cancer requires platinum + paclitaxel + bevacizumab + pembrolizumab for PD-L1 CPS >= 1 (KEYNOTE-826); tisotumab vedotin provides an active second-line ADC option requiring strict ocular mitigation.
Last updated: August 2026
8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies
Gynecologic malignancies encompass distinct anatomical and molecular entities: Epithelial Ovarian Cancer (EOC) , Endometrial Carcinoma , and Cervical Cancer . Recent advancements in precision oncology have transformed gynecologic cancer care through the integration of Homologous Recombination Deficiency (HRD) testing, The Cancer Genome Atlas (TCGA) molecular classification , Mismatch Repair (MMR) profiling, and novel Antibody-Drug Conjugates (ADCs) .
Board-certified oncology pharmacists must command the molecular diagnostics, pharmacotherapy regimens, toxicities, and supportive care protocols governing these malignancies.
1. Epithelial Ovarian Cancer: Primary Therapy & Maintenance Algorithms
High-Grade Serous Ovarian Cancer ( HGSOC ) represents ~70–80% of ovarian malignancies and is characterized by ubiquitous TP53 mutations and high rates of Homologous Recombination Repair Deficiency (HRD) (~50% of tumors harbor germline/somatic BRCA1/2 mutations or non- BRCA HRD genomic scarring).
Primary Cytoreduction & Frontline Systemic Chemotherapy
Primary Debulking Surgery: The cornerstone of initial management. Surgical goal is complete cytoreduction (R0: no gross macroscopic residual disease) or optimal debulking (<1 cm residual).
Frontline Platinum-Taxane Doublet:
Carboplatin (AUC 5–6 IV) + Paclitaxel (175 mg/m2 IV over 3 hours) every 21 days for 6 cycles.
Dose-Dense Paclitaxel (JGOG 3016 / GOG-262): Paclitaxel 80 mg/m2 IV weekly on Days 1, 8, 15 + Carboplatin AUC 6 Q3W.
Bevacizumab Incorporation (GOG-218 / ICON7): Bevacizumab (15 mg/kg IV Q3W) added to cycles 2–6 and continued as maintenance for 15–22 total cycles in patients with Stage III suboptimally debulked (>1 cm residual) or Stage IV disease. +-----------------------------------------------------------------------------+
- | FRONTLINE OVARIAN CANCER MAINTENANCE ALGORITHM |
- | |
- | RESPONSE (CR or PR) TO FRONTLINE PLATINUM-BASED CHEMOTHERAPY |
- | (Determine: Germline/Somatic BRCA1/2 Mutation and HRD Genomic Status) |
- | | |
- | +-------------------------+-------------------------+ |
- | | | |
- | v v |
- | [gBRCA or sBRCA MUTATED] [BRCA WILD-TYPE] |
- | (SOLO-1 Trial: Moore NEJM 2018) | |
- | - **OLAPARIB MONOTHERAPY** | |
- | 300 mg PO BID for 2 YEARS | |
- | - 7-year OS: **67.0% vs. 46.5%** | |
- | (OS HR 0.55, p = 0.0004) | |
- | - OR Olaparib + Bevacizumab (PAOLA-1) | |
- | - OR Niraparib Monotherapy (PRIMA) | |
- | | |
- | +-----------------------------------------+ |
- | | | |
- | v v |
- | [HRD-POSITIVE / BRCA WT] [HRD-NEGATIVE / HRP] |
- | (PAOLA-1 & PRIMA Trials) (Homologous Recomb Prof) |
- | - Option 1: **OLAPARIB + BEVACIZUMAB** (PAOLA-1) - Option 1: **BEVACIZUMAB|
- | * Olaparib 300 mg BID x 2 yrs + Bevacizumab MONOTHERAPY** (GOG-218)|
- | 15 mg/kg Q3W x 15 mos (mPFS 37.2 vs 17.7m; 15 mg/kg Q3W to finish |
- | HR 0.33, p < 0.0001) 15-22 cycles |
- | - Option 2: **NIRAPARIB MONOTHERAPY** (PRIMA) - Option 2: **NIRAPARIB**|
- | * Individualized 200/300 mg daily x 3 years (Modest PFS HR 0.68) |
- | - Option 3: OBSERVATION |
- | - *(Olaparib is NOT rec)*|
- +-----------------------------------------------------------------------------+
- Platinum-Sensitive vs. Platinum-Resistant Recurrent Disease
Platinum-Sensitive Recurrence (Platinum-Free Interval [PFI] >= 6 months): Rechallenge with platinum-based doublet: Carboplatin + Pegylated Liposomal Doxorubicin (PLD) (preferred over paclitaxel per CALYPSO due to lower neuropathy/alopecia), Carboplatin + Gemcitabine +/- Bevacizumab (OCEANS), or Carboplatin + Paclitaxel +/- Bevacizumab (GOG-213). Followed by PARP inhibitor maintenance if PARP-naive.
Platinum-Resistant Recurrence (PFI < 6 months): Poor prognosis; single-agent non-platinum cytotoxic therapy (PLD, weekly paclitaxel, topotecan, gemcitabine) +/- Bevacizumab (AURELIA trial: adds bevacizumab 10 mg/kg Q2W or 15 mg/kg Q3W, doubling ORR and PFS). +-----------------------------------------------------------------------------+
- | MIRVETUXIMAB SORAVTANSINE IN PLATINUM-RESISTANT EOC |
- | |
- | [TARGET & MOLECULAR STRUCTURE] (MIRASOL Trial: Moore et al. NEJM 2023) |
- | - Anti-Folate Receptor Alpha (**FRalpha**) Monoclonal Antibody ADC |
- | - Payload: **DM4** (Potent maytansinoid microtubule-disrupting agent) |
- | - Indication: FRalpha-positive (>=75% tumor cells with >=2+ intensity by |
- | Ventana FOLR1 Assay) platinum-resistant ovarian cancer (1-3 prior lines)|
- | - Dosing: **6 mg/kg Adjusted Ideal Body Weight (AIBW) IV Q3W** |
- | - Efficacy: Superior PFS (HR 0.65) and OS (**16.5 vs. 12.8 months**, |
- | HR 0.67, p = 0.0046) over physician's choice chemotherapy! |
+-----------------------------------------------------------------------------+ +-----------------------------------------------------------------------------+
- | MANDATORY MIRVETUXIMAB OPHTHALMIC CARE PROTOCOL |
- | |
- | - Pathophysiology: DM4 payload uptake into corneal epithelial cells |
- | causes microcystic corneal deposits, keratopathy, and visual blurring. |
- | |
- | [PRE-TREATMENT & ONGOING SURVEILLANCE] |
- | - Baseline comprehensive ophthalmic exam (visual acuity + slit lamp). |
- | - Repeat ophthalmic exam every cycle for first 8 cycles, then Q2 cycles. |
- | |
- | [MANDATORY TOPICAL PROPHYLAXIS] |
- | 1. Topical Corticosteroid Eye Drops: Prednisolone acetate 1% (or equivalent|
- | dexamethasone) **1 drop in each eye TID on Days 1 to 8** of each cycle. |
- | 2. Lubricating Eye Drops (Artificial Tears): Preservative-free drops |
- | instilled **at least 4 to 6 times daily** while awake throughout Tx. |
- | 3. Contact Lens Prohibition: Avoid contact lenses during entire treatment |
- | until at least 30 days after treatment discontinuation. |
- +-----------------------------------------------------------------------------+
- 2. Endometrial Carcinoma: TCGA Molecular Classification & Therapeutics
Endometrial carcinoma is the most common gynecologic malignancy in developed countries. The traditional Bokhman classification (Type I endometrioid vs. Type II serous/clear cell) has been superseded by The Cancer Genome Atlas (TCGA) / Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) molecular stratification: +-----------------------------------------------------------------------------+
- | TCGA / ProMisE MOLECULAR CLASSIFICATION |
- | |
- | 1. POLE ULTRAMUTATED (~10%): |
- | - Exonuclease domain mutations in DNA polymerase epsilon (*POLE*) |
- | - Ultra-high tumor mutational burden (>100 mut/Mb); marked immune infil|
- | - **PROGNOSIS: EXCELLENT.** Virtually 0% recurrence; candidates for |
- | de-escalation (omission of adjuvant chemo/radiation). |
- | |
- | 2. MISMATCH REPAIR DEFICIENT / MSI-HIGH (dMMR / MSI-H; ~25-30%): |
- | - Loss of MLH1, MSH2, MSH6, or PMS2 (Lynch Syndrome or MLH1 promoter |
- | hypermethylation). High microsatellite instability and high TMB. |
- | - **PROGNOSIS: INTERMEDIATE.** Outstanding responsiveness to Immune |
- | Checkpoint Inhibitors (Dostarlimab, Pembrolizumab). |
- | |
- | 3. p53 ABNORMAL / SEROUS-LIKE / COPY NUMBER-HIGH (p53abn; ~15%): |
- | - *TP53* missense/null mutation; diffuse p53 IHC overexpression/null. |
- | - High genomic instability, aneuploidy; ~30% HER2 amplification. |
- | - **PROGNOSIS: POOR / AGGRESSIVE.** High recurrence; requires intensive|
- | chemotherapy (Carboplatin+Paclitaxel +/- Trastuzumab if HER2+). |
- | |
- | 4. NO SPECIFIC MOLECULAR PROFILE / COPY NUMBER-LOW (NSMP; ~45-50%): |
- | - *POLE* WT, MMR-intact (pMMR), p53-wild-type. Highly ER/PR positive. |
- | - **PROGNOSIS: INTERMEDIATE.** Responsive to hormonal therapies. |
- +-----------------------------------------------------------------------------+
Advanced & Metastatic Endometrial Cancer Pharmacotherapy +-----------------------------------------------------------------------------+
- | ADVANCED / RECURRENT ENDOMETRIAL CANCER TREATMENT MATRIX |
- | |
- | [FRONTLINE dMMR / MSI-HIGH POPULATION] |
- | - **RUBY Trial (Mirza et al. NEJM 2023):** |
- | * Carboplatin (AUC 5) + Paclitaxel (175 mg/m2) + **DOSTARLIMAB** (500mg)|
- | Q3W x 6 cycles -> Dostarlimab Maintenance (1000 mg Q6W for 3 years) |
- | * 24-month PFS: **61.4% vs. 15.7%** (HR 0.28, p < 0.0001) |
- | - **NRG-GY018 / KEYNOTE-868 (Eskander et al. NEJM 2023):** |
- | * Carboplatin + Paclitaxel + **PEMBROLIZUMAB** (200 mg Q3W -> 400 mg Q6W)|
- | * PFS HR: **0.30** (p < 0.0001) in dMMR cohort |
- | |
- | [SECOND-LINE pMMR / MSS POPULATION (KEYNOTE-775 / Study 309)] |
- | - **LENVATINIB** (20 mg PO daily) + **PEMBROLIZUMAB** (200 mg IV Q3W) |
- | - Significantly superior to doxorubicin/paclitaxel: Median OS **17.4 vs. |
- | 12.0 months** (HR 0.68, p < 0.0001); Median PFS **6.6 vs. 3.8 months** |
- | - Toxicity Management: Proactive blood pressure control (Grade 3 HTN 42%),|
- | proteinuria, diarrhea, weight loss, dysphonia, fistula surveillance. |
- | |
- | [SECOND-LINE dMMR / MSI-HIGH MONOTHERAPY] |
- | - **Dostarlimab** 500 mg Q3W x 4, then 1000 mg Q6W (GARNET Trial) OR |
- | - **Pembrolizumab** 200 mg Q3W or 400 mg Q6W (KEYNOTE-158 Trial) |
- | |
- | [ADVANCED HER2-OVEREXPRESSING p53abn SEROUS CARCINOMA] |
- | - Carboplatin + Paclitaxel + **Trastuzumab** (Fader et al. JCO 2018/2020) |
- | - Prolongs median PFS (12.6 vs 8.0 mo, HR 0.44) and OS (29.6 vs 24.4 mo) |
- +-----------------------------------------------------------------------------+
- 3. Cervical Carcinoma: Prevention, Chemoradiation & Metastatic Strategies
Virtually all cervical carcinomas (>95%) are etiologically linked to persistent infection with high-risk Human Papillomavirus (HPV) subtypes, predominantly HPV-16 (~50–60%) and HPV-18 (~15–20%). Viral oncoproteins E6 (which binds and accelerates ubiquitin-mediated degradation of p53 ) and E7 (which binds and inactivates retinoblastoma protein pRb ) drive genomic instability and uninhibited G1/S cell cycle progression.
Prevention & Primary Screening
Primary Prevention: Recombinant 9-valent HPV vaccine ( Gardasil-9 , covering HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58). Recommended at age 11–12 years (2-dose series if started before age 15; 3-dose series at 0, 1–2, 6 months if started at age >=15 or in immunocompromised individuals). FDA approved up to age 45.
Secondary Prevention: High-risk HPV DNA co-testing and cervical cytology (Pap smear).
Locally Advanced Cervical Cancer (FIGO Stage IB3–IVA)
The standard of care is definitive Concurrent Chemoradiation (CCRT) combining External Beam Radiation Therapy (EBRT) and Image-Guided Brachytherapy with radiosensitizing weekly Cisplatin :
Cisplatin Dosing: 40 mg/m2 IV weekly (maximum single dose: 70 mg ) administered 1–2 hours prior to radiation on Days 1, 8, 15, 22, 29 (for 5–6 weekly doses during EBRT).
Mechanism of Radiosensitization: Cisplatin inhibits the sublethal repair of radiation-induced DNA double-strand breaks, synchronizes malignant cells into the radiosensitive G2/M phase, and overcomes hypoxic radioresistance.
KEYNOTE-A18 Integration: In high-risk locally advanced cervical cancer (FIGO 2014 Stage III–IVA, or Stage IB2–IIB node-positive), adding Pembrolizumab (200 mg Q3W x 5 cycles concurrent with CCRT, followed by 400 mg Q6W for up to 15 maintenance cycles) significantly prolonged PFS and OS.
Metastatic / Recurrent Cervical Cancer Therapeutics +-----------------------------------------------------------------------------+
- | METASTATIC / RECURRENT CERVICAL CANCER ALGORITHMS |
- | |
- | [FRONTLINE STANDARD (PD-L1 CPS >= 1)] (KEYNOTE-826: Monk NEJM 2021) |
- | - **PEMBROLIZUMAB + PLATINUM + PACLITAXEL +/- BEVACIZUMAB** |
- | * Pembrolizumab: 200 mg IV Q3W |
- | * Cisplatin: 50 mg/m2 IV Q3W (OR Carboplatin AUC 5 IV Q3W) |
- | * Paclitaxel: 175 mg/m2 IV Q3W |
- | * Bevacizumab: 15 mg/kg IV Q3W (Omit if high fistula/perforation risk) |
- | - Landmark Efficacy: Median OS **28.6 vs. 16.5 months** (HR 0.64, p<0.001)|
- | |
- | [SECOND-LINE ADC: TISOTUMAB VEDOTIN] (innovaTV 301: de Bono NEJM 2024) |
- | - Target: **Tissue Factor (TF)** overexpressed in cervical cancer |
- | - Payload: **Monomethyl auristatin E (MMAE)** (Microtubule inhibitor) |
- | - Dose: **2.0 mg/kg IV Q3W** (Max 200 mg) |
- | - Significant OS prolongation (HR 0.70, p = 0.0038) over chemotherapy |
+-----------------------------------------------------------------------------+ +-----------------------------------------------------------------------------+
- | MANDATORY TISOTUMAB VEDOTIN EYE CARE PROTOCOL |
- | |
- | - Pathophysiology: TF expression in conjunctiva + MMAE uptake induces |
- | conjunctivitis, blepharitis, keratitis, and corneal ulceration (50-60%).|
- | |
- | [PROTOCOLIZED 4-STEP OCULAR MITIGATION BUNDLE] |
- | 1. Ophthalmic Vasoconstrictor: Instill **Brimonidine tartrate 0.2%** (or |
- | phenylephrine) eye drops in each eye immediately prior to infusion. |
- | 2. External Cold Therapy: Apply **cooling eye pads / gel packs** bilaterally|
- | over closed eyes during the entire 30-minute IV infusion. |
- | 3. Topical Steroid Eye Drops: Instill **Dexamethasone 0.1%** (or equiv) |
- | eye drops 1 drop TID in each eye on **Days 1, 2, and 3** of each cycle. |
- | 4. Lubricating Drops: Preservative-free artificial tears >= 4 times daily.|
- | - Strictly prohibit contact lenses for duration of treatment. |
- +-----------------------------------------------------------------------------+
- 4. Gynecologic Oncology Master Pharmacotherapy Matrix
Cancer Type Setting / Subtype Preferred Regimen & Dosing Landmark Trial Citation Clinical Pharmacist Interventions & Monitoring
Ovarian Frontline Maintenance (g/sBRCAm) Olaparib: 300 mg PO BID for 2 years SOLO-1 (Moore et al. NEJM 2018) Monthly CBC for anemia/neutropenia; monitor SCr (OCT2/MATE1 inhibition). Dose reduce to 200 mg BID for CrCl 31–50 mL/min.
Ovarian Frontline Maintenance (HRD-Positive) Olaparib: 300 mg PO BID x 2 yrs + Bevacizumab: 15 mg/kg Q3W x 15 mos PAOLA-1 (Ray-Coquard et al. NEJM 2019) Dual mechanism: PARP trapping + anti-angiogenesis. Monitor BP, urine protein/creatinine ratio, cytopenias.
Ovarian Platinum-Resistant (FRalpha-High) Mirvetuximab Soravtansine: 6 mg/kg AIBW IV Q3W MIRASOL (Moore et al. NEJM 2023) Mandatory eye care: Prednisolone 1% eye drops TID on D1–8; lubricating artificial tears QID; periodic slit-lamp exams. Peripheral neuropathy surveillance.
Endometrial Advanced / Primary Recurrent (dMMR / MSI-H) Dostarlimab: 500 mg Q3W x 6 cycles (+ Carbo/Pac) -> 1000 mg Q6W x 3 yrs RUBY (Mirza et al. NEJM 2023) Immune checkpoint inhibitor irAE monitoring (thyroid, colitis, pneumonitis, hepatitis). Outstanding durability in dMMR.
Endometrial Advanced Recurrent (pMMR / MSS) Lenvatinib: 20 mg PO daily + Pembrolizumab: 200 mg IV Q3W KEYNOTE-775 (Makker et al. NEJM 2022) Severe hypertension: Initiate amlodipine/ACEi proactively. Monitor proteinuria, TSH (hypothyroidism in >50%), fistula/perforation.
Cervical Locally Advanced (Stage IB3–IVA) Cisplatin: 40 mg/m2 IV weekly (max 70 mg) x 5–6 doses + Radiotherapy Standard CCRT / KEYNOTE-A18 Cisplatin is a radiosensitizer. Ensure aggressive pre/post hydration (1 L NS) and weekly monitoring of serum creatinine, potassium, and magnesium.
Cervical Metastatic Frontline (PD-L1 CPS >= 1) Pembrolizumab: 200 mg Q3W + Carbo (AUC 5) / Cisplatin (50 mg/m2) + Paclitaxel (175 mg/m2) + Bevacizumab (15 mg/kg) KEYNOTE-826 (Monk et al. NEJM 2021) Screen for vesicovaginal / rectovaginal fistula risk before administering bevacizumab. Prophylactic G-CSF for 4-drug myelosuppression.